EpiVax Therapeutics Overview
- Year Founded
-
2017
- Status
-
Out of Business
- Employees
-
3
- Latest Deal Type
-
Out of Business
EpiVax Therapeutics General Information
Description
Operator of a clinical research and development platform intended to offer precision cancer immunotherapies. The company's platform is based on optimal neo-epitopes selected through proprietary and validated in-silico predictive algorithms, enabling clients to address the unmet medical needs that are inadequately addressed by current cancer therapeutic approaches.
Contact Information
Website
www.epivaxtx.comCorporate Office
- 188 Valley Street
- Suite 424
- Providence, RI 02909
- United States
Corporate Office
- 188 Valley Street
- Suite 424
- Providence, RI 02909
- United States
EpiVax Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Out of Business | 02-Apr-2026 | Completed | Out of Business | |||
| 7. Secondary Transaction - Private | Completed | Generating Revenue | ||||
| 6. Later Stage VC | 26-Jan-2022 | Completed | Generating Revenue | |||
| 5. Early Stage VC (Series A) | 22-Feb-2021 | Completed | Generating Revenue | |||
| 4. Seed Round | 25-May-2018 | Completed | Startup | |||
| 3. Seed Round | 25-Sep-2017 | Completed | Startup | |||
| 2. Accelerator/Incubator | 12-Dec-2017 | Completed | Startup | |||
| 1. Accelerator/Incubator | Completed | Startup |
EpiVax Therapeutics Comparisons
Industry
Financing
Details
EpiVax Therapeutics Competitors (2)
One of EpiVax Therapeutics’s 2 competitors is Nexoplex bio, a Formerly VC-backed company based in Emeryville, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Nexoplex bio | Formerly VC-backed | Emeryville, CA | ||||
| BioNTech | Formerly VC-backed | Mainz, Germany |
EpiVax Therapeutics Patents
EpiVax Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20210145951-A1 | Compositions and methods for shared neo-epitope vaccines | Inactive | 18-Nov-2019 | ||
| CA-3158646-A1 | Improved compositions and methods for shared neo-epitope vaccines | Pending | 18-Nov-2019 | ||
| EP-4062177-A1 | Improved compositions and methods for shared neo-epitope vaccines | Inactive | 18-Nov-2019 | ||
| US-20220362365-A1 | Improved compositions and methods for shared neo-epitope vaccines | Inactive | 18-Nov-2019 | ||
| WO-2021101962-A1 | Improved compositions and methods for shared neo-epitope vaccines | Inactive | 18-Nov-2019 | G01N33/575 |
EpiVax Therapeutics Signals
EpiVax Therapeutics FAQs
-
When was EpiVax Therapeutics founded?
EpiVax Therapeutics was founded in 2017.
-
Where is EpiVax Therapeutics headquartered?
EpiVax Therapeutics is headquartered in Providence, RI.
-
What is the size of EpiVax Therapeutics?
EpiVax Therapeutics has 3 total employees.
-
What industry is EpiVax Therapeutics in?
EpiVax Therapeutics’s primary industry is Drug Discovery.
-
Is EpiVax Therapeutics a private or public company?
EpiVax Therapeutics is a Private company.
-
What is EpiVax Therapeutics’s current revenue?
The current revenue for EpiVax Therapeutics is .
-
How much funding has EpiVax Therapeutics raised over time?
EpiVax Therapeutics has raised $3.07M.
-
Who are EpiVax Therapeutics’s competitors?
Nexoplex bio and BioNTech are competitors of EpiVax Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process